system and a gelatinase-inducing bioassay. It was demonstrated that two aromatic amino acid residues, namely, Phe 7 and Trp 10 , in the ring region of GBAP are strongly involved in the GBAP-FsrC interaction and subsequent FsrC activation. Furthermore, we performed structural analysis of GBAP by nuclear magnetic resonance (NMR) spectroscopy to clarify its solution conformation; we found that Trp 10 contributed to the stabilization of the compact form of the GBAP ring region.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The strains used in this study are listed in Table 1 . E. faecalis OG1RF (9) was used as the standard gelatinasepositive strain to examine the GBAP agonist/antagonist activity of each synthetic peptide. E. faecalis OU510 has an amber mutation in fsrB, resulting in a lack of GBAP biosynthesis. This strain was used as the responder strain for the GBAP agonist activity assay because gelatinase production in this strain completely depends on exogenously added GBAP (28) . All E. faecalis strains were cultured in 36.4 g/liter Todd-Hewitt broth (THB) (Oxoid, Basingstoke, Hampshire, United Kingdom) at 37°C with gentle agitation. Lactococcus lactis NZ9000 (17) carrying pNZfsrC-his6 was cultivated in 42.5 g/liter M17 medium (Merck, Darmstadt, Germany) supplemented with 0.5% glucose and 10 g ml Ϫ1 of chloramphenicol (GM17MC) at 30°C without agitation.
Peptide synthesis. All the cyclic peptides used in this study, except disulfide-GBAP, were synthesized according to a previously developed scheme in which the linear peptides were dehydrated between the hydroxyl group of Ser 3 and the carboxyl group at the C terminus (27) . The protected linear peptides were manually synthesized by a solid-phase peptide synthesis method using p-alkoxybenzoyl alcohol resin (Wang resin) (Kokusan Kagaku, Tokyo, Japan) as a solid support (4) . The side-chain-protecting groups of the 9-fluorenylmethoxy carbonyl amino acids were as follows: the trityl (Trt) group for asparagine [Asn (Trt) . The N-terminally protected linear peptides were obtained by exposure to 86.5% trifluoroacetic acid (TFA), 5% phenol, 5% water, 2.5% ethanedithiol, and 1% triisopropylsilane, and subsequent cyclization was performed using benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium-hexafluorophosphate as previously described (27) . Finally, mature cyclic peptides were cleaved from N-terminally protected cyclic peptides by exposure to a solution containing 76% TFA, 7.5% thioanisole, 7.5% ethanedithiol, 7.5% m-cresol, and 1.5% TFA anhydride.
To synthesize N-acetyl desQ 1 -GBAP and N-acetyl desQ 1 N 2 -GBAP, 240 g of desQ 1 -GBAP and 70 g of desQ 1 N 2 -GBAP were dissolved in a solution containing 200 l acetic anhydride and 200 l pyridine and kept overnight at 37°C.
Disulfide-GBAP was synthesized by incubating 25 mg of a deprotected linear peptide, H 2 N-Gln-Asn-Cys-Pro-Asn-Ile-Phe-Gly-Gln-Trp-Cys-OH, with 10% acetic acid (25 ml) (pH 7.8) and 0.1 M potassium ferricyanide (520 l) at 37°C for 20 min.
Fluorescence-labeled peptides for the receptor-binding assay were prepared by reacting unlabeled peptides with fluorescein-4-isothiocyanate (FITC; Dojindo, Kumamoto, Japan) (13 All crude peptides were purified by reverse-phase high-performance liquid chromatography (RP-HPLC) using an Inertsil octadecyl silane-3 column (5 m, 4.6 by 150 mm; GL Sciences Inc., Tokyo, Japan) after cleanup of the reaction mixture with a Sep-pak C 18 cartridge column (Waters, MA). The HPLC conditions that were employed were as follows: the solvent system was water containing 0.1% TFA (A solution) and acetonitrile containing 0.1% TFA (B solution), elution was performed with a linear gradient of 20 to 60% B solution for 40 min, the flow rate was 1 ml min Ϫ1 , and UV detection was done at 220 nm. The molecular weights of all resulting peptides were ascertained by electrospray ionization mass spectroscopy (AccuTOF T100LC; Jeol, Tokyo, Japan).
GBAP agonist and antagonist assay. For the GBAP agonist assay, E. faecalis OU510 was used as the responder strain. The use of this strain allows the measurement of GBAP agonist activity in each tested peptide without the additive effect of endogenously produced GBAP. A culture of E. faecalis OU510 grown overnight was inoculated at an optical density at 660 nm (OD 660 ) of 0.02 into 5 ml of THB medium containing 10 nM of each synthetic tested peptide and then grown at 37°C with gentle agitation. E. faecalis OU510 cells grown in THB medium containing 10 nM of GBAP served as the control. The culture supernatant was collected 5 h after the inoculation, and the gelatinase activity induced in the supernatant was measured using azocoll (Ͻ50 mesh; Calbiochem, San Diego, CA) as the substrate for gelatinase according to a protocol described previously (20, 26) . Briefly, 40 l of the culture supernatant was added to 0.8 ml of the azocoll substrate solution and incubated for 4 h at 37°C on a shaker (170 rpm) (SN-30B; Nissin Scientific Corp., Tokyo, Japan). The mixture was centrifuged at 20,000 ϫ g for 5 min, and the OD 540 of the supernatant was measured.
E. faecalis OG1RF was used as the responder strain for the GBAP agonist/ antagonist assay. In general, this strain produces approximately 10 nM GBAP in the late exponential phase of culture. Since OG1RF endogenously produces GBAP, which autoinduces gelatinase production, not only agonist activity but also antagonist activity can be simultaneously examined in this assay; an activity higher than 100% means agonist activity, and an activity lower than 100% means antagonist activity. A culture of E. faecalis OG1RF grown overnight was inoculated to an OD 660 of 0.02 into 5 ml of THB medium containing 1,000 nM of each synthetic peptide and was then grown at 37°C with gentle agitation. E. faecalis OG1RF grown in THB medium containing 1,000 nM of GBAP served as a control. The culture supernatant was collected 5 h after the inoculation, and the gelatinase activity induced in the supernatant was measured as described above. Overexpression of FsrC on Lactococcus lactis. Plasmid pNZ8048 is a vector allowing the nisin-controlled expression of genes of interest; this vector was used for the expression of hexahistidine-tagged fsrC (8, 17) (Table 1 ). An fsrC gene fragment was PCR amplified using KOD Plus DNA polymerase (Toyobo, Osaka, Japan) with E. faecalis OG1RF chromosomal DNA as the template and the following primers: fsrC-his6-F1 (5Ј-CCCTGAATCATGATTTTGTCGTTATTA GC-3Ј) and fsrC-his6-R (5Ј-AATACCGAGCTCTTAATGATGATGATGATG ATGTTCGTTAACAACTTTTTTACTG-3Ј) The latter sequence contains a SacI site (indicated by underlining) for cloning. The amplified fragment was used as the template for the reamplification of fsrC gene fragments with the following primers: fsrC-his6-F2 (5Ј-CCGAATCTGCAGAAATGATTTTGTCGTTA-3Ј) and fsrC-his6-R. The former sequence has a PstI site (indicated by underlining) for cloning. The obtained fragments and pNZ8048 were digested with the restriction enzymes PstI (Takara Bio Inc., Shiga, Japan) and SacI (Roche, Indianapolis, IN) and then both ligated by using the Ligation-high kit (Toyobo). The resulting plasmid, pNZfsrC-his6, was introduced into Lactococcus lactis NZ9000 by electroporation according to previously developed methods (16) . The transformed fsrC gene was sequenced to confirm that no mutation had occurred. L. lactis NZ9000 harboring vector pNZ8048 and without the fsrC-His 6 gene was used as the control. A culture of recombinant L. lactis NZ9000 cells grown overnight was inoculated into 200 ml of fresh GM17MC. After the culture reached an OD 600 of 0.5, nisin A (Sigma-Aldrich, Inc., St. Louis, MO) dissolved in water and adjusted to pH 3.0 with HCl was added to achieve a final concentration of 10 ng ml Ϫ1 for the induction of the fsrC-His 6 gene. The culture was maintained for 3 h for the expression of FsrC-His 6 .
To confirm the overexpression of FsrC-His 6 , the cells were harvested, suspended in 50 mM Tris-HCl (pH 7.5), and treated with 25 g ml Ϫ1 of lysozyme for 30 min at 37°C. The resulting spheroplasts were disrupted using an ultrasonic disintegrator. The membrane fraction was separated by ultracentrifugation at 125,000 ϫ g for 90 min and sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by Western blot analysis using anti-histidine tag antibody to detect FsrC-His 6 . Western blot analysis was performed using the Penta-His HRP conjugate kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol.
Fluorescence-based receptor-binding assay. After the induction of recombinant L. lactis cells, the cells were harvested and washed with 50 mM Tris-HCl (pH 7.8), and the cell concentration was adjusted to an OD 600 of 10. One hundred microliters of cell suspension was added to a 1.5-ml tube containing an equal volume of 2 M of each FITC-labeled peptide. The mixture was then incubated for 1 h at 30°C with shaking (120 rpm) (SN-30B; Nissin Scientific Corp.). Subsequently, the mixture was centrifuged at 6,000 ϫ g for 3 min, and the cell pellet was washed thoroughly three times with 50 mM Tris-HCl (pH 7.8).
The washed cells were resuspended in 100 l of 50 mM Tris-HCl (pH 7.8) and observed under a fluorescent microscope (Eclipse 80i; Nikon, Tokyo, Japan). To quantify the fluorescence-labeled peptides bound to L. lactis transformant cells, the cell suspension was added into 2 ml of water in the microcell containing 0.25% (vol/vol) Triton X-100 and 2.5 M of 5-dimethylamino-1-naphthalenesulfonyl (DNS)-phosphatidyl-ethanolamine as the internal standard. The fluorescence intensity of the mixture was measured at an absorbance (emission wavelength) of 520 nm, with excitation wavelengths ranging from 300 to 500 nm. A fluorophotometer (F-7000; Hitachi, Tokyo, Japan) (the excitation wavelengths of FITC and DNS are 495 nm and 340 nm, respectively) was used for this purpose. The fluorescence intensity of FITC was normalized to that of DNS-phosphatidylethanolamine.
NMR spectroscopy. 1 H-1 H two-dimensional NMR data, i.e., DQF-COSY (double-quantum filtered-correlation spectroscopy), TOCSY (total correlation spectroscopy) (50-ms mixing time), and NOESY (nuclear Overhauser effect spectroscopy) (100-, 200-, 300-, 400-, and 500-ms mixing times) for 1.5 mM GBAP dissolved in 90% H 2 O-10% D 2 O (vol/vol) (pH 6.0, direct meter reading) were collected at 10°C using a Unity Inova 500 spectrometer (Varian, CA). 1 H-15 N two-dimensional NMRs (natural-abundance 1 H-15 N HSQC [heteronuclear single-quantum coherence]) of 1.5 mM wild-type and F 7 A-and W 10 AGBAPs dissolved in the same solution described above were collected at 10°C using a Unity Inova 600 spectrometer (Varian). The acquired NMR data were processed, visualized, and peak picked with the software packages NMRPipe, NMRDraw (6), and SPARKY (12), respectively. Sequential assignments (35) were accomplished. Structure calculations were performed with the program CYANA (14) , with 105 distance restraints and 8 angle restraints obtained from NOESY (200-ms mixing time) and DQF-COSY, respectively. A total of 20 structures were selected from 100 calculated structures on the basis of their values of CYANA target function and were then subjected to restrained energy minimization in the CNS program (3) with the ester bond restrain between Ser 3 and Met 11 in addition to the NMR-derived restrains. As a result, an ensemble of the 10 lowest-energy structures was retained. The molecular structure was visualized with the program PyMOL (7).
CD spectroscopy. Circular dichroism (CD) spectra of wild-type and F 7 A-and W 10 A-GBAPs were recorded with a Jasco (Tokyo, Japan) J-720 spectrometer using a cuvette with a path length of 1 mm (far-UV) at 25°C. The concentration of each peptide used in the CD spectroscopy was 50 M dissolved in 10% CH 3 CN solution. CD spectra were collected with the slit width set to 1 nm, a response time of 2 s, and a scan speed of 50 nm/min. Spectra were measured three times and averaged. Ellipticity was measured from 200 to 250 nm at 1-nm intervals, corrected for a 10% CH 3 CN solution baseline, and converted to molar ellipticity () that is expressed as ϫ 10 
RESULTS

SAR in ring linker moiety.
To address the ring linker structure required for GBAP activity, we synthesized several lactone group-substituted analogues (lactam, thiolactone, CH 2 -lactone, and disulfide) ( Fig. 2A) . To compare the agonist activities of these analogues to that of GBAP, each peptide was assayed at 10 nM by using E. faecalis OU510 as the responder strain ( Table 1 ). The use of this strain allowed us to determine the GBAP agonist activity without the additive effect of endogenously produced GBAP.
Lactam-GBAP showed a similar level of agonist activity as GBAP, while thiolactone-GBAP showed a slightly lower level of agonist activity than GBAP (Fig. 2B) . CH 2 -lactone-GBAP showed the same level of agonist activity as GBAP, indicating that the linker chain length is not a critical factor influencing this activity. In contrast, disulfide-GBAP lost its agonist activity, although its linker chain length was consistent with that of CH 2 -lactone-GBAP (Fig. 2B) . Disulfide-GBAP did not show any agonist and antagonist activities even at 1,000 nM, while M 11 A-GBAP showed significant agonist activity at 100 nM (Fig. 2C) ; the activity corresponds to 10 nM GBAP. This suggests that the carbonyl group in the ring linker moiety but not the side chain of C-terminal residues is important for the ligand-receptor interaction.
SAR in the tail region. The SAR in the tail region was examined. A series of N-terminally truncated GBAP analogues (desQ 1 -GBAP and desQ 1 N 2 -GBAP) were synthesized, and their GBAP agonist activities were measured. desQ 1 -GBAP showed approximately 60% of the agonist activity exhibited by GBAP, and desQ 1 N 2 -GBAP showed no agonist activity (Fig.  3A) . However, N-terminal acetylation of desQ 1 N 2 -GBAP (AcdesQ 1 N 2 -GBAP) partially restored its agonist activity, suggesting that the amide bond at the N-terminal side of Ser 3 is the minimum recognition unit for the agonist activity. The antagonist activity of desQ 1 N 2 -GBAP against GBAP was also examined. E. faecalis OU510 was incubated in THB medium containing 10, 100, or 1,000 nM of desQ 1 N 2 -GBAP in the presence of 10 nM GBAP, and the induced gelatinase activity was measured. For the negative control, no desQ 1 N 2 -GBAP was added to the medium. As a result, no inhibitory effect of the addition (Fig. 3B) .
Next, we performed alanine substitutions in the tail amino acids. Three analogues (Q 1 A-, N 2 A-, and Q 1 A-N 2 A-GBAPs) were synthesized, and their agonist activities were measured (Fig. 3A) . These alanine substitutions did not affect their agonist activities, indicating that the side chains in the tail amino acids are not involved in GBAP agonist activity.
SAR in the ring region. Except for Ser 3 , which was involved in the formation of the lactone linkage, all the amino acid GBAP agonist activity of the ring linker-substituted analogues. E. faecalis OU510 was cultured for 5 h in the presence of 10 nM each synthetic peptide, and the induced gelatinase activity in the culture supernatant was measured as GBAP agonist activity by azocoll assay according to a previously described protocol (20, 26) . The activity of 10 nM GBAP (black bar) was determined to normalize the agonist activity of each peptide. The averages Ϯ standard deviations of duplicate determinations are presented. (C) GBAP agonist/antagonist activity of disulfide-GBAP and M 11 A-GBAP. Activity higher than 100% means agonist activity, and activity lower than 100% means antagonist activity. E. faecalis OG1RF was cultured for 5 h in the presence of various concentrations of each synthetic peptide. For the control, the induced gelatinase activity was measured in the strain cultured without the addition of exogenous peptide (black bar) and was used to normalize the agonist/antagonist activity of each peptide. The induced gelatinase activity in the culture supernatant was measured by azocoll assay. The averages Ϯ standard deviations of duplicate determinations are presented. residues in the ring region were subjected to alanine scanning (Fig. 1) . The GBAP agonist assay revealed that all the alaninesubstituted analogues showed almost no activity at 10 nM, indicating that the whole structure of the ring region is crucial for GBAP agonist activity (Fig. 4A) . Next, an agonist/antagonist assay was performed for these alanine-substituted analogues at a 100-fold-higher concentration (1,000 nM) by using E. faecalis OG1RF as the responder strain. As shown in Fig. 4B , none of the analogues exhibited antagonist activity, whereas except for F 7 A-and W 10 AGBAPs, all analogues showed marked agonist activities at 1,000 nM. W 10 A-GBAP did not show any agonist activity, while F 7 A-GBAP showed very weak agonist activity at 1,000 nM. These findings suggest that two aromatic amino acids, Phe 7 and Trp 10 , are key residues for receptor interaction and activation; notably, Trp 10 is essential for the agonist activity. SAR at Trp 10 . In order to investigate the function of the essential residue Trp 10 in more detail, it was substituted with natural and unnatural aromatic amino acids. To evaluate the hydrophobicity of each peptide, the retention times of these aromatic analogues by RP-HPLC were examined (Fig. 5) . Except for the tyrosine-substituted analogue (W 10 Y-GBAP), the retention times of all other aromatic analogues were longer than that of GBAP, indicating that the hydrophobicity of these aromatic analogues was higher than that of GBAP. Subsequently, the agonist activity of each aromatic analogue was measured at various concentrations (Fig. 5) . Almost all aromatic analogues showed significant agonist activity at 1,000 nM. The 1-naphtylalanine-substituted analogue (Nal 1 -GBAP), the 3-benzothienylalanine-substituted analogue (Bal 3 -GBAP), and the phenylalanine-substituted analogue (W 10 F-GBAP) in particular showed the same level of agonist activity as GBAP at each concentration. W 10 Y-GBAP showed significantly lower levels of agonist activity at all concentrations tested. On the other hand, the pentafluorophenylalanine-substituted analogue (Phe f5 -GBAP) and the cyclohexylalanine-substituted analogue (Cha-GBAP) showed no agonist activity regardless of their high level of hydrophobicity. Furthermore, Phe f5 - FIG. 4 . SAR in the ring region. (A) GBAP agonist activities of alanine-substituted analogues. The activity of each 10 nM synthetic peptide was measured and normalized to that of 10 nM GBAP (black bar) as described in the legend of Fig. 2B . The averages Ϯ standard deviations of duplicate determinations are presented. (B) GBAP agonist/antagonist activity of alanine-substituted analogues. Activity higher than 100% means agonist activity, and activity lower than 100% means antagonist activity. E. faecalis OG1RF was cultured for 5 h in the presence of 1,000 nM of each synthetic peptide. For the control, the induced gelatinase activity was measured in the strain cultured without the addition of exogenous peptide (black bar) and was used to normalize the agonist/antagonist activity of each peptide. The induced gelatinase activity in the culture supernatant was measured by an azocoll assay. The averages Ϯ standard deviations of duplicate determinations are presented. (Fig. 7A ). This agrees with a previous finding that the acetylation of the ␣-amino group at the N terminus does not greatly influence the GBAP agonist activity (27) . flu-GBAP was incubated with FsrC-overexpressing cells, and the bound peptide was monitored by fluorescent microscopy (Fig. 7B) . Luminescence of cells was observed only for the FsrC-overexpressing cells, indicating specific GBAP binding to FsrC. On the other hand, flu-F 7 A-GBAP and flu-W 10 A-GBAP did not bind to the FsrC-overexpressing cells. Receptor binding was also quantified by measuring the fluorescence of the labeled cells with a fluorophotometer. In this assay, F 7 A-GBAP and flu-W 10 A-GBAP did not show significant receptor binding (Fig. 7C) . This indicates that these two aromatic groups in the ring region are strongly involved in GBAP binding to FsrC.
NMR structural analysis of GBAP. Two-dimensional proton NMR spectra of GBAP were measured at pH 6.0 and 10°C, and sequential assignments were completed. The structure calculation of GBAP was performed by using the CYANA and CNS programs with 105 distance restraints and 8 angle restraints. Finally, 10 structures with the lowest energy in the CNS program were chosen to represent the solution structure of GBAP (Fig. 8 ). An ensemble of the 10 structures exhibited CNS total energies of 240.8 Ϯ 8.9 kcal/mol and root mean square deviations (RMSDs) of 0.20 Ϯ 0.07 Å (backbone atoms) and 0.79 Ϯ 0.12 Å (all heavy atoms) in the GBAP ring region. The structural statistics are summarized in Table 2 . GBAP adopted a hairpin-like fold where Phe 7 and Gly 8 formed a distorted ␤-turn. The peptide backbone of the ring region was rigid, while that of the tail region was flexible. The side chain of Phe 7 was extended to the solvent and freely rotating. The side chain of Trp 10 was partially buried inside the ring and fixed. Indeed, a series of NOEs were observed between the indole proton of Trp 10 and the methylene proton of Asn 5 . Comparison of spectral properties of F 7 A-GBAP and W 10 A-GBAP to those of wild-type GBAP. In order to briefly compare the secondary structures of two inactive analogues, F 7 A-and W 10 A-GBAPs, to that of GBAP, CD spectra of the three peptides were measured (Fig. 9) . Wild-type GBAP and F 7 A-GBAP exhibited a negative band at 215 nm. This band was suspected to reflect the ␤-turn structure as observed in the
On the other hand, W 10 A-GBAP did not show any band in the far-UV region. This suggests that F 7 A-GBAP retains the same secondary structure as wild-type GBAP, whereas W 10 A-GBAP does not.
Comparison of the tertiary structure among three peptides was performed by 1 H-15 N heteronuclear NMR spectroscopy. Figure 10 shows the overlaid spectra of those three peptides. Several minor cross-peaks were observed in the spectrum of W 10 A-GBAP, indicating that W 10 A-GBAP forms multiple conformations. In contrast, only one set of cross-peaks was observed in those of wild-type GBAP and F 7 A-GBAP. Except for amides of Asn 2 in wild-type GBAP and F 7 A-GBAP, all one-bond 1 H-15 N couplings were detected as cross-peaks. The chemical shifts from F 7 A-GBAP were mostly close to those of the corresponding atoms in wild-type GBAP, whereas those from W 10 A-GBAP were totally different from those of wildtype GBAP. Since chemical shifts of amide protons and nitrogens reflect the chemical environment of their atoms in the solution, their differences between wild-type GBAP and analogues suggest a difference in peptide backbone conformations. Taken together, F 7 A-GBAP, but not W 10 A-GBAP, retained the conformation of wild-type GBAP. FIG. 9 . CD spectra of wild-type GBAP (circle), F 7 A-GBAP (triangle), and W 10 A-GBAP (square). All peptide concentrations employed were 50 M dissolved in 10% CH 3 CN solution. Data were corrected for a 10% CH 3 CN solution baseline. The path length and resolution were 1 mm and 1 nm, respectively. Spectra were measured three times and averaged. 
DISCUSSION
This SAR study demonstrated the following: (i) the carbonyl group at the ring linker moiety is essential for the GBAP agonist activity (Fig. 2B and C) ; (ii) the side chain of the tail residues is not involved in the agonist activity, and an amide bond at the N-terminal side of Ser 3 is the minimum recognition unit for GBAP agonist activity (Fig. 3) ; and (iii) the entire ring region is involved in the agonist activity, and notably, two aromatic residues, Phe 7 and Trp 10 , are strongly involved in the receptor-ligand interaction (Fig. 4, 5, and 7) . With regard to the role of the side chains in the tail residues, staphylococcal AIP differs from GBAP, since the tail region is also important for inducer activity in staphylococcal AIP. However, N-terminally truncated AIP-II and AIP-IV, when present in nM concentrations, antagonized all four groups of AIPs (18, 19) . On the other hand, N-terminally truncated GBAP (desQ 1 N 2 -GBAP) at 1 M could not antagonize the GBAP activity (Fig.  3B) . These discrepancies suggest that the molecular interaction mechanism between AIP and AgrC does not correspond to that between GBAP and FsrC.
To examine the receptor-binding activity of GBAP independent of its physiological activity, we constructed new fluorescence-based receptor-binding assay systems by using fluorescent microscopy and a fluorophotometer, which can be used to detect ligand binding to FsrC. In both fluorescent microscopy and fluorophotometer assays, it was clearly shown that flu-GBAP specifically bound onto FsrC-overexpressing cells (Fig.  7B) , suggesting that these assay systems were useful for examining ligand-receptor interactions. In these assays, flu-F 7 A-GBAP and flu-W 10 A-GBAP showed no binding to FsrC-overexpressing cells (Fig. 7B and C) . Considering this and the data for physiological activity, we conclude that these two aromatic amino acids are key residues for the GBAP-FsrC interaction. Trp 10 could be substituted with certain natural and unnatural aromatic amino acids without a loss of agonist activity, while Cha-GBAP showed no agonist activity (Fig. 5) . This indicates that the -electron cloud on the aromatic ring surface is important for the agonist activity. Furthermore, we showed that Phe f5 -GBAP, which carries a positively charged -electron cloud, lost its agonist activity, suggesting the importance of a negative electrostatic potential on the aromatic ring surface (Fig. 5) . This was also indicated by the fact that W 10 Y-GBAP, which carries a -electron cloud with less negative charge, showed a much lower agonist activity.
The NMR structural analysis revealed that the ring region of GBAP adopted a hairpin-like fold and was tightly packed into a compact form (Fig. 8) . In Fig. 11 , each residue is colored according to their relative importances for the agonist activity. It was feasible that residues classified into each category were clustered. Notably, two aromatic residues, Phe 7 and Trp 10 , colored purple, appeared to be important for the receptorligand interaction, as supported by both biological and binding activity assays. Of the two important aromatic residues, the side chain of Phe 7 was extended outside the ring and was probably directly involved in receptor binding. On the other hand, the side chain of Trp 10 was partially buried inside the ring region and contributed to the stabilization of the compact form, probably in addition to the direct receptor binding (Fig.  8, 9, and 10) .
In this study, we have gained some knowledge on the SAR of GBAP in the context of its biological activity and receptorbinding property by using our newly constructed receptorbinding assay systems. Interestingly, the molecular interaction mechanism between GBAP and FsrC does not correspond to that between AIPs and AgrC in staphylococci, suggesting that a rational design of staphylococcal AIP antagonist cannot directly be applied for the development of a GBAP antagonist. We also gained insight into the tertiary structure of GBAP, in which Trp 10 is a key residue to retain the compact ring formation. The total pharmacophore information obtained in this study should be applied to the further development of the peptide-based rational design of GBAP antagonists.
